OBJECTIVE: We sought to understand how Affordable Care Act (ACA) Medicaid expansion insurance coverage gains are associated with changes in diabetes-related biomarkers. RESEARCH DESIGN AND METHODS: This was a retrospective observational cohort study using electronic health record data from 178 community health centers (CHCs) in the ADVANCE (Accelerating Data Value Across a National Community Health Center Network) network. We assessed changes in diabetes-related biomarkers among adult patients with diabetes in 10 Medicaid expansion states (n = 25,279), comparing newly insured with continuously insured, discontinuously insured, and continuously uninsured patients pre- to post-ACA expansion. Primary outcomes included changes from 24 months pre- to 24 months post-ACA in glycosylated hemoglobin (HbA1c), systolic (SBP) and diastolic (DBP) blood pressure, and LDL cholesterol levels. RESULTS: Newly insured patients exhibited a reduction in adjusted mean HbA1c levels (8.24% [67 mmol/mol] to 8.17% [66 mmol/mol]), which was significantly different from continuously uninsured patients, whose HbA1c levels increased (8.12% [65 mmol/mol] to 8.29% [67 mmol/mol]; difference-in-differences [DID] -0.24%; P < 0.001). Newly insured patients showed greater reductions than continuously uninsured patients in adjusted mean SBP (DID -1.8 mmHg; P < 0.001), DBP (DID -1.0 mmHg; P < 0.001), and LDL (DID -3.3 mg/dL; P < 0.001). Among patients with elevated HbA1c in the 3 months prior to expansion, newly insured patients were more likely than continuously uninsured patients to have a controlled HbA1c measurement by 24 months post-ACA (hazard ratio 1.25; 95% CI 1.02-1.54]. CONCLUSIONS: Post-ACA, newly insured patients had greater improvements in diabetes-related biomarkers than continuously uninsured, discontinuously insured, or continuously insured patients. Findings suggest that health insurance gain via ACA facilitates access to appropriate diabetes care, leading to improvements in diabetes-related biomarkers.
OBJECTIVE: We sought to understand how Affordable Care Act (ACA) Medicaid expansion insurance coverage gains are associated with changes in diabetes-related biomarkers. RESEARCH DESIGN AND METHODS: This was a retrospective observational cohort study using electronic health record data from 178 community health centers (CHCs) in the ADVANCE (Accelerating Data Value Across a National Community Health Center Network) network. We assessed changes in diabetes-related biomarkers among adult patients with diabetes in 10 Medicaid expansion states (n = 25,279), comparing newly insured with continuously insured, discontinuously insured, and continuously uninsured patients pre- to post-ACA expansion. Primary outcomes included changes from 24 months pre- to 24 months post-ACA in glycosylated hemoglobin (HbA1c), systolic (SBP) and diastolic (DBP) blood pressure, and LDL cholesterol levels. RESULTS: Newly insured patients exhibited a reduction in adjusted mean HbA1c levels (8.24% [67 mmol/mol] to 8.17% [66 mmol/mol]), which was significantly different from continuously uninsured patients, whose HbA1c levels increased (8.12% [65 mmol/mol] to 8.29% [67 mmol/mol]; difference-in-differences [DID] -0.24%; P < 0.001). Newly insured patients showed greater reductions than continuously uninsured patients in adjusted mean SBP (DID -1.8 mmHg; P < 0.001), DBP (DID -1.0 mmHg; P < 0.001), and LDL (DID -3.3 mg/dL; P < 0.001). Among patients with elevated HbA1c in the 3 months prior to expansion, newly insured patients were more likely than continuously uninsured patients to have a controlled HbA1c measurement by 24 months post-ACA (hazard ratio 1.25; 95% CI 1.02-1.54]. CONCLUSIONS: Post-ACA, newly insured patients had greater improvements in diabetes-related biomarkers than continuously uninsured, discontinuously insured, or continuously insured patients. Findings suggest that health insurance gain via ACA facilitates access to appropriate diabetes care, leading to improvements in diabetes-related biomarkers.
Authors: Daniel Polsky; Michael Richards; Simon Basseyn; Douglas Wissoker; Genevieve M Kenney; Stephen Zuckerman; Karin V Rhodes Journal: N Engl J Med Date: 2015-01-21 Impact factor: 91.245
Authors: Rachel Springer; Miguel Marino; Jean P O'Malley; Stephan Lindner; Nathalie Huguet; Jennifer E DeVoe Journal: Med Care Date: 2018-05 Impact factor: 2.983
Authors: Brigit Hatch; Steffani R Bailey; Stuart Cowburn; Miguel Marino; Heather Angier; Jennifer E DeVoe Journal: Am J Public Health Date: 2016-02-18 Impact factor: 9.308
Authors: Daniel R Hogan; Goodarz Danaei; Majid Ezzati; Philip M Clarke; Ashish K Jha; Joshua A Salomon Journal: Health Aff (Millwood) Date: 2015-09 Impact factor: 6.301
Authors: Gregory A Nichols; Jay Desai; Jennifer Elston Lafata; Jean M Lawrence; Patrick J O'Connor; Ram D Pathak; Marsha A Raebel; Robert J Reid; Joseph V Selby; Barbara G Silverman; John F Steiner; W F Stewart; Suma Vupputuri; Beth Waitzfelder Journal: Prev Chronic Dis Date: 2012-06-07 Impact factor: 2.830
Authors: Jennifer E DeVoe; Rachel Gold; Erika Cottrell; Vance Bauer; Andrew Brickman; Jon Puro; Christine Nelson; Kenneth H Mayer; Abigail Sears; Tim Burdick; Jonathan Merrell; Paul Matthews; Scott Fields Journal: J Am Med Inform Assoc Date: 2014-05-12 Impact factor: 4.497
Authors: Melanie T Chen; Danielle M Krzyszczyk; Alison G M Brown; Nancy Kressin; Norma Terrin; Amresh Hanchate; Jillian Suzukida; Sucharita Kher; Lori Lyn Price; Amy M LeClair; Elena Byhoff; Karen M Freund Journal: J Racial Ethn Health Disparities Date: 2021-05-19
Authors: Karen R Siegel; Edward W Gregg; Obidiugwu Kenrik Duru; Lizheng Shi; Carol M Mangione; Pamela L Thornton; Steve Clauser; Mohammed K Ali Journal: BMJ Open Diabetes Res Care Date: 2021-12